Related Experiment Video

Updated: May 9, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient

R Hirschhorn, V Roegner, A Rubinstein

    The Journal of Clinical Investigation
    |March 1, 1980
    PubMed

    Insights

    Adenosine deaminase (ADA) deficiency in infants causes elevated deoxyadenosine and deoxyadenosine triphosphate (dATP) levels at birth. These findings in cord blood may explain early immune dysfunction and lymphopenia in affected newborns.

    Area of Science:

    • Biochemistry
    • Immunology
    • Genetics

    Background:

    • Adenosine deaminase (ADA) deficiency is a rare genetic disorder.
    • It leads to the accumulation of toxic metabolites, impacting immune system development.
    • Prenatal diagnosis allows for early intervention and study of neonatal effects.

    Observation:

    • Cord blood from an infant diagnosed with ADA deficiency was analyzed.
    • Concentrations of adenosine, deoxyadenosine, and deoxyadenosine triphosphate (dATP) were measured.
    • Plasma deoxyadenosine and adenosine levels were significantly elevated at birth.

    Findings:

    • Plasma deoxyadenosine elevation was documented for the first time in newborns with ADA deficiency.
    • Erythrocyte dATP content was markedly increased at birth compared to normal levels.
    • These elevated metabolite concentrations mirror those in older ADA-deficient patients.

    Implications:

    • The observed metabolite levels may underlie the impaired immune function and lymphopenia seen at birth in ADA deficiency.
    • Early detection and understanding of these biochemical markers are crucial for managing ADA deficiency.
    • This study highlights the prenatal impact of ADA deficiency on nucleotide metabolism and immune health.

    More Related Videos

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme04:17

    Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

    Published on: September 27, 2024

    Related Concept Videos

    Hydrolysis of ATP01:08

    Hydrolysis of ATP

    The bonds of adenosine triphosphate (ATP) can be broken through the addition of water, releasing one or two phosphate groups in an exergonic process called hydrolysis. This reaction liberates the energy in the bonds for use in the cell—for instance, to synthesize proteins from amino acids.
    If one phosphate group is removed, a molecule of ADP—adenosine diphosphate—remains, along with inorganic phosphate. ADP can be further hydrolyzed to AMP—adenosine monophosphate—by the removal of a second...
    ATP Energy Storage and Release01:31

    ATP Energy Storage and Release

    ATP is a highly unstable molecule. Unless quickly used to perform work, ATP spontaneously dissociates into ADP and inorganic phosphate (Pi), and the free energy released during this process is lost as heat. The energy released by ATP hydrolysis is used to perform work inside the cell and depends on a strategy called energy coupling. Cells couple the exergonic reaction of ATP hydrolysis with endergonic reactions, allowing them to proceed.
    One example of energy coupling using ATP involves a...
    Inborn Errors of Metabolism01:20

    Inborn Errors of Metabolism

    Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Biosynthesis of Nucleic Acids01:28

    Biosynthesis of Nucleic Acids

    Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...